netFormulary NHS
Northern Lincolnshire
Formulary
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
Notes:

The Constipation Pathway can be viewed here

 

The Stoma Care Appliances Guideline can be viewed here

http://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2018/08/stoma-care-Northern-Lincolnshire-Area-prescribing-Committee-Guidelines-for-the-Prescribing-v1-20180614.pdf

 

Continence Formulary ( NEL) can be vie here :

http://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2018/10/MOPP-024-V1-Continence-Formulary-NEL-2.pdf

 

 Details...
01.05.03  Expand sub section  Drugs affecting the immune response
Cytotoxic Drug Azathioprine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Tablets

 
 
Ciclosporin (Neoral )
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Neoral 25mg, 50mg & 100mg  capsules

Neoral 100mg/ml  oral solution 50ml

Deximune 25mg, 50mg and 100mg capsules - to be used by dermatology only

 
 
Cytotoxic Drug Mercaptopurine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Tablets

 
 
Cytotoxic Drug Methotrexate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

2.5mg tablets

 
 
Mycophenolate Mofetil
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

capsules

 
 
01.05.03  Expand sub section  Cytokine inhibitors : Treatment of ulcerative colitis and Crohn’s diseaseTwo biosimilar versions of
Adalimumab
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

To be in accordance with the associated NICE Technical Appraisals  

 
Link  NICE TA187: Crohn’s disease - infliximab and adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
 
Golimumab
(Ulcerative Colitis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

to be used in accordance with NICE TA329

 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
 
Infliximab
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA187: Crohns disease - infliximab & adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
 
Ustekinumab  (Stelera ®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 456: Ustekinumab for moderately to severe active crohns disease after previous treatment
Link  NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
 
VedolizumabBlack Triangle
(Gastroenterology)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine

to be used in accordance with NICE TA352 and NICE TA342

 
Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
 
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Green -Medicines suitable for routine use within primary care and Secondary care Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies  

Amber

Amber- Medicines suitable to be prescribed in primary care after specialist /Consultant recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust Medicines and Therapeutic Committee and approved by the Area Prescribing Committee.   

Red

Red-Hospital initiation and continuation only  

Amber Shared Care Protocol

AMBER SHARE CARE PROTOCOL- Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised  

Blue

To be supplied from the appropriate commissioned provider.   

Green 2

GREEN 2- to be prescribed by primary care only   

Grey

GREY- NON FORMULARY (As agreed by Area Prescribing Committee)  

netFormulary